Julie Garver
Family · Venice, FLNPI 1962096768
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 30.6% of the total. Reporting peaked in 2022 at $1,592 and has fallen 95.6% since, to $71 in 2024.
Across 207 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$367
- Nestle Healthcare Nutrition Inc.$310
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$290
- Merck$177
- Johnson & Johnson$173
- plus $998 from 17 others
What the payments were for
- Food & beverage$3,335100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $1,021 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $367 |
| Nestle Healthcare Nutrition Inc. | 24 | $310 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $290 |
| Merck | 12 | $177 |
| Johnson & Johnson | 13 | $173 |
| Ardelyx, Inc. | 5 | $166 |
| Daiichi Sankyo Inc. | 9 | $144 |
| Evoke Pharma, Inc. | 2 | $118 |
| Gilead | 2 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $86 |
| QOL Medical, LLC | 5 | $86 |
| Bristol Myers Squibb | 3 | $42 |
| Lucid Diagnostics Inc. | 2 | $38 |
| Pfizer | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Organon | 4 | $29 |
| Braintree Laboratories, Inc. | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $26 |
| Intercept Pharmaceuticals, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,335 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $96,313 |
| LinzessLinaclotide | 16 | $11,098 |
| Pantoprazole Sodium | 63 | $731 |
| Esomeprazole Magnesium | 21 | $565 |
| Sucralfate | 15 | $356 |
| Famotidine | 31 | $345 |
| Omeprazole | 32 | $300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,021 | $11,09816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Venice
- Lindsey WatfordVenice$43K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.